Therapeutic targeting of non-coding RNAs in cancer

J 2017

Therapeutic targeting of non-coding RNAs in cancer

SLABÝ, Ondřej, R. LAGA a O. SEDLACEK

Základní údaje

Originální název

Therapeutic targeting of non-coding RNAs in cancer

Autoři

SLABÝ, Ondřej (203 Česká republika, garant, domácí), R. LAGA (203 Česká republika) a O. SEDLACEK (203 Česká republika)

Vydání

Biochemical Journal, LONDON, PORTLAND PRESS LTD, 2017, 0264-6021

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10608 Biochemistry and molecular biology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.857

Kód RIV

RIV/00216224:14740/17:00100445

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1042/BCJ20170079

UT WoS

000423617100004

Klíčová slova anglicky

NATURAL ANTISENSE TRANSCRIPTS; MICRORNA REPLACEMENT THERAPY; CHRONIC LYMPHOCYTIC-LEUKEMIA; MOUSE VASCULAR ENDOTHELIUM; NEGATIVE BREAST-CANCER; SMALL INTERFERING RNAS; TOLL-LIKE RECEPTORS; CELL LUNG-CANCER; SIRNA DELIVERY; IN-VIVO

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 3. 2018 15:28, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

The majority of the human genome encodes RNAs that do not code for proteins. These non-coding RNAs (ncRNAs) affect normal expression of the genes, including oncogenes and tumour suppressive genes, which make them a new class of targets for drug development in cancer. Although microRNAs (miRNAs) are the most studied regulatory ncRNAs to date, and miRNA-targeted therapeutics have already reached clinical development, including the mimics of the tumour suppressive miRNAs miR-34 and miR-16, which reached phase I clinical trials for the treatment of liver cancer and mesothelioma, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognised. Here, we describe obstacles and advances in the development of ncRNA therapeutics and provide the comprehensive overview of the ncRNA chemistry and delivery technologies. Furthermore, we summarise recent knowledge on the biological functions of miRNAs and their involvement in carcinogenesis, and discuss the strategies of their therapeutic manipulation in cancer. We review also the emerging insights into the role of lncRNAs and their potential as targets for novel treatment paradigms. Finally, we provide the up-to-date summary of clinical trials involving miRNAs and future directions in the development of ncRNA therapeutics.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

Citovat

SLABÝ, Ondřej, R. LAGA a O. SEDLACEK. Therapeutic targeting of non-coding RNAs in cancer. Biochemical Journal. LONDON: PORTLAND PRESS LTD, 2017, roč. 474, DEC, s. 4219-4251. ISSN 0264-6021. Dostupné z: https://dx.doi.org/10.1042/BCJ20170079.

@article{1411968,
   author = {Slabý, Ondřej and Laga, R. and Sedlacek, O.},
   article_location = {LONDON},
   article_number = {DEC},
   doi = {http://dx.doi.org/10.1042/BCJ20170079},
   keywords = {NATURAL ANTISENSE TRANSCRIPTS; MICRORNA REPLACEMENT THERAPY; CHRONIC LYMPHOCYTIC-LEUKEMIA; MOUSE VASCULAR ENDOTHELIUM; NEGATIVE BREAST-CANCER; SMALL INTERFERING RNAS; TOLL-LIKE RECEPTORS; CELL LUNG-CANCER; SIRNA DELIVERY; IN-VIVO},
   language = {eng},
   issn = {0264-6021},
   journal = {Biochemical Journal},
   title = {Therapeutic targeting of non-coding RNAs in cancer},
   url = {http://www.biochemj.org/content/474/24/4219},
   volume = {474},
   year = {2017}
}

TY  - JOUR
ID  - 1411968
AU  - Slabý, Ondřej - Laga, R. - Sedlacek, O.
PY  - 2017
TI  - Therapeutic targeting of non-coding RNAs in cancer
JF  - Biochemical Journal
VL  - 474
IS  - DEC
SP  - 4219-4251
EP  - 4219-4251
PB  - PORTLAND PRESS LTD
SN  - 02646021
KW  - NATURAL ANTISENSE TRANSCRIPTS
KW  - MICRORNA REPLACEMENT THERAPY
KW  - CHRONIC LYMPHOCYTIC-LEUKEMIA
KW  - MOUSE VASCULAR ENDOTHELIUM
KW  - NEGATIVE BREAST-CANCER
KW  - SMALL INTERFERING RNAS
KW  - TOLL-LIKE RECEPTORS
KW  - CELL LUNG-CANCER
KW  - SIRNA DELIVERY
KW  - IN-VIVO
UR  - http://www.biochemj.org/content/474/24/4219
L2  - http://www.biochemj.org/content/474/24/4219
N2  - The majority of the human genome encodes RNAs that do not code for proteins. These non-coding RNAs (ncRNAs) affect normal expression of the genes, including oncogenes and tumour suppressive genes, which make them a new class of targets for drug development in cancer. Although microRNAs (miRNAs) are the most studied regulatory ncRNAs to date, and miRNA-targeted therapeutics have already reached clinical development, including the mimics of the tumour suppressive miRNAs miR-34 and miR-16, which reached phase I clinical trials for the treatment of liver cancer and mesothelioma, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognised. Here, we describe obstacles and advances in the development of ncRNA therapeutics and provide the comprehensive overview of the ncRNA chemistry and delivery technologies. Furthermore, we summarise recent knowledge on the biological functions of miRNAs and their involvement in carcinogenesis, and discuss the strategies of their therapeutic manipulation in cancer. We review also the emerging insights into the role of lncRNAs and their potential as targets for novel treatment paradigms. Finally, we provide the up-to-date summary of clinical trials involving miRNAs and future directions in the development of ncRNA therapeutics.
ER  -

SLABÝ, Ondřej, R. LAGA a O. SEDLACEK. Therapeutic targeting of non-coding RNAs in cancer. \textit{Biochemical Journal}. LONDON: PORTLAND PRESS LTD, 2017, roč.~474, DEC, s.~4219-4251. ISSN~0264-6021. Dostupné z: https://dx.doi.org/10.1042/BCJ20170079.

Podrobný výpis o publikaci